Browsing by Author Barrios, Carlos

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2014ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)+Houssami, Nehmat; Aapro, Matti S.; Andre, Fabrice; Barrios, Carlos; Bergh, Jonas (Prof); Biganzoli, L; Blackwell, K L; Cardoso, Fatima; Costa, Alberto; et al, .; Norton, Larry W; Senkus, E; School of Public Health: Public HealthESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)+, The Breast, vol.23, 5, 2014,pp 489-502
2014Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseBoyle, Frances; Barrios, Carlos; De Azambuja, Evandro; Di Cosimo, Serena; et al, Various; Holmes, Andrew P; Holmes, Eileen; Jackisch, Christian; Lang, Istvan; Perez, E. A.; Piccart-Gebhart, Martine; Smith, Ian (Prof); Swaby, Ramona F; Untch, Michael; Xu, Binghe; Northern Clinical School: MedicineLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response, The Lancet Oncology, vol.15, 10, 2014,pp 1137-1146
2012Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung CancerBoyer, Michael; Barrios, Carlos; Blackhall, Fiona; Bover, Isabel; et al, Various; Frank, Richard; Heo, Dae Seog; Krzakowski, Maciej; Park, Keunchil; Ramalingam, Suresh; Rosell, Rafael Costa; Talbot, Denis; Central Clinical School: MedicineRandomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.30, 27, 2012,pp 3337-3344